340 completed, 70 terminated, 22 unknown, 20 active not recruiting. 260 Phase 2, 247 Phase 1, 21 Phase 3, 18 Not applicable, 8 Early Phase 1.
Follow Gliosarcoma: new trials by email Literature Review of Gliosarcoma trials Research Report on Gliosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Metronomic Temozolomide With Dexbrompheniramine for Recurrent High-Grade Glioma/Glioblastoma Dexbrompheniramine, Temozolomide - High Grade Glioma, Glioblastoma | Phase 1 / Phase 2 | Not yet recruiting | University of Nebraska | 41 | 2027-06-01 | 2026-10-05 |
| Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma Actinium Ac 225 Lintuzumab, Biospecimen Collection, Cemiplimab - Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma | Phase 1 | Not yet recruiting | National Cancer Institute (NCI) | 30 | 2026-12-04 | 2026-06-12 |
| GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma Biospecimen Collection, Bispecific CD80-lgG4Fc-IL-2v Fusion Protein GI-102, Computed Tomography - Glioblastoma, IDH-Wildtype, Progressive Astrocytoma, IDH-Mutant, Grade 4 | Phase 2 | Recruiting | Mayo Clinic | 36 | 2026-08-03 | 2026-10-01 |
| Phase I Pilot Study to Evaluate the Anti-glioblastoma Effect of S-Gboxin in Standard Treatment of Glioblastoma/Diffuse Midline Glioma and Response to Treatment (Regardless of Mutation Status) S-Gboxin - Glioblastoma Multiforme, Diffuse Midline Glioma, H3 K27M-Mutant | Phase 1 | Suspended | Petrov, Andrey | 10 | 2026-05-20 | 2026-06-03 |
| ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial Biospecimen Collection, Echocardiography Test, EGFR Inhibitor ERAS-801 - Glioblastoma, Glioblastoma, IDH-Wildtype | Phase 1 | Recruiting | Jonsson Comprehensive Cancer Center | 50 | 2025-07-28 | 2026-09-18 |
| A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment. Ipilimumab (3 mg/kg) - Glioblastoma, Gliosarcoma, Adult | Phase 1 | Recruiting | University College, London | 16 | 2025-07-10 | 2026-04-09 |
| A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma C134 - Glioblastoma, Glioblastoma (GBM) | Phase 1 | Active not recruiting | James Markert, MD | 12 | 2025-06-02 | 2026-08-13 |
| Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma ERAS-801, ABBV-637, ABBV-155 - Glioblastoma, Gliosarcoma | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 60 | 2025-04-07 | 2026-09-09 |
| Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue Specimen Collection - Glioblastoma, Glioblastoma Multiforme | Recruiting | Baptist Health South Florida | 120 | 2024-12-11 | 2026-02-04 | |
| Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma Balstilimab, Botensilimab, Liposomal Doxorubicin - Newly Diagnosed Glioblastoma, Glioblastoma, Isocitric Dehydrogenase (IDH)-Wildtype | Phase 2 | Active not recruiting | Northwestern University | 25 | 2024-01-19 | 2026-09-29 |
| A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma PCI 24781, Temozolomide - Recurrent High Grade Glioma, Anaplastic Astrocytoma | Phase 1 | Recruiting | University of Nebraska | 24 | 2023-06-26 | 2026-09-14 |
| Prognostic Potential of Olfactory Function in Glioblastoma: a Prospective Observational Study olfactory testing (threshold and identification test) - Glioblastoma Multiforme, Adult, Glioblastoma or Gliosarcoma | Recruiting | Sied Kebir | 128 | 2023-05-03 | 2026-08-24 | |
| Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM Cord Blood-derived Expanded Allogeneic Natural Killer Cells, Resection - Recurrent Gliosarcoma, Recurrent Supratentorial Glioblastoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 25 | 2023-04-28 | 2026-09-04 |
| Intracavitary Photodynamic Therapy as an Adjuvant to Resection of Glioblastoma or Gliosarcoma Using IV Photobac® photochemotherapy using 3-(1-Butyloxy)ethyl-3-deacetyl-bacteriopurpurin-18-n-butylimide methyl ester(Photobac®) - Glioblastoma Multiforme of Brain, Glioma, Sarcomatous | Phase 1 | Unknown | Photolitec LLC | 30 | 2023-04-11 | 2023-04-13 |
| Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma Biospecimen Collection, Efineptakin alfa, Pembrolizumab - High Grade Astrocytic Tumor, Recurrent Glioblastoma, IDH-Wildtype | Phase 2 | Active not recruiting | Mayo Clinic | 53 | 2023-01-24 | 2026-10-05 |
| Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma Atezolizumab, Cabozantinib - Recurrent Glioblastoma, Recurrent Gliosarcoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 47 | 2022-09-23 | 2026-08-25 |
| Natural Progesterone for the Treatment of Recurrent Glioblastoma Quality-of-Life Assessment, Questionnaire Administration, Therapeutic Progesterone - Gliosarcoma, Recurrent Glioblastoma | Early Phase 1 | Terminated | Emory University | 4 | 2022-04-11 | 2026-05-05 |
| Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma Lomustine, Magnetic Resonance Imaging, Photon Beam Radiation Therapy - Glioblastoma, Gliosarcoma | Phase 3 | Active not recruiting | NRG Oncology | 265 | 2022-03-28 | 2026-08-17 |
| Study of Pembrolizumab and M032 (NSC 733972) M032, Pembrolizumab - Glioblastoma Multiforme, Anaplastic Astrocytoma | Phase 1 / Phase 2 | Recruiting | University of Alabama at Birmingham | 28 | 2022-02-25 | 2026-01-22 |
| Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma TMZ, ipilimumab 3mg/kg, Nivolumab - Glioblastoma, Gliosarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 47 | 2021-12-08 | 2026-04-17 |
Showing 20 of 487. Sign in to see all of them.
Glioblastoma (476) · Brain Neoplasms (272) · Astrocytoma (230) · Central Nervous System Neoplasms (223) · Glioma (191) · Oligodendroglioma (176) · Ependymoma (77) · Medulloblastoma (42) · Neuroectodermal Tumors, Primitive (42) · Glioma, Subependymal (41) · Meningioma (34) · Pinealoma (26) · Choroid Plexus Neoplasms (22) · Craniopharyngioma (20)
Neoplasms, Glandular and Epithelial (485) · Neoplasms by Histologic Type (484) · Neoplasms, Nerve Tissue (484) · Neoplasms, Germ Cell and Embryonal (483) · Neuroectodermal Tumors (482) · Neoplasms, Neuroepithelial (477) · Neoplasms (474) · Neoplasms by Site (363) · Nervous System Neoplasms (362) · Nervous System Diseases (361) · Glioma (296) · Central Nervous System Diseases (286) · Brain Diseases (285) · Astrocytoma (248) · Central Nervous System Neoplasms (141)
Temozolomide (132) · Radiotherapy (87) · Bevacizumab (43) · Radiation (31) · Carmustine (29) · Magnetic Resonance Spectroscopy (23) · Erlotinib Hydrochloride (22) · Irinotecan (22) · Chemotherapy, Adjuvant (20) · Surgical Procedures, Operative (16) · O(6)-benzylguanine (15) · Carboplatin (14) · Radiotherapy, Conformal (13) · Radiotherapy, Intensity-Modulated (13) · sargramostim (12)
National Cancer Institute (NCI) (94) · Duke University (37) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (34) · M.D. Anderson Cancer Center (22) · Jonsson Comprehensive Cancer Center (15) · European Organisation for Research and Treatment of Cancer - EORTC (13) · City of Hope Medical Center (11) · Case Comprehensive Cancer Center (10) · Memorial Sloan Kettering Cancer Center (10) · Radiation Therapy Oncology Group (10) · Alliance for Clinical Trials in Oncology (9) · New Approaches to Brain Tumor Therapy Consortium (9) · Northwestern University (9) · Wake Forest University Health Sciences (8) · University of California, San Francisco (7)
United States (429) · Canada (30) · Switzerland (16) · United Kingdom (16) · France (13) · Netherlands (13) · Germany (10) · Italy (10) · Belgium (8) · Australia (7) · Spain (7) · Austria (6) · Israel (5) · Brazil (2) · Colombia (2)
Stuart A. Grossman, MD (12) · Annick Desjardins, MD, FRCPC (10) · David A. Reardon, MD (8) · Henry S. Friedman, MD (8) · Darell D. Bigner, MD, PhD (6) · Michael Prados, MD (6) · Evanthia Galanis (5) · Howard A. Fine, MD (5) · Jeffrey J. Raizer, MD (5) · Roger Stupp, MD (5) · Annick Desjardins, MD (4) · David Peereboom, MD (4) · Edward G. Shaw, MD (4) · Jana Portnow (4) · Jana Portnow, MD (4)
PMID 25113840, PMID 23377664, PMID 24309981, PMID 33842889, PMID 38197800, PMID 10394416, PMID 10549493, PMID 11410496, PMID 11772431, PMID 12573762, PMID 12721262, PMID 12749710, PMID 14670747, PMID 14769135, PMID 14769136, PMID 14769138, PMID 15073861, PMID 15251162, PMID 15292713, PMID 15465203, PMID 15667958, PMID 15758009, PMID 15758010, PMID 15809479, PMID 15890570, PMID 16012795, PMID 16033132, PMID 16034522, PMID 16053699, PMID 16061868, PMID 16133802, PMID 16170172, PMID 16192602, PMID 16203762, PMID 16321761, PMID 16443947, PMID 16549835, PMID 16735709, PMID 16750317, PMID 16817692, PMID 16877732, PMID 16877733, PMID 16914578, PMID 17031561, PMID 17264335, PMID 17317837, PMID 17470857, PMID 17560737, PMID 17609661, PMID 17694310
U01CA062475 (23), U01CA137443 (11), U10CA025224 (11), U01CA062399 (10), P30CA006973 (8), U10CA021661 (8), P30CA033572 (7), U10CA180868 (7), P30CA043703 (6), U10CA180821 (5), UM1CA137443 (5), P30CA006516 (4), P30CA008748 (3), P30CA022453 (3), P30CA138292 (3)